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ABSTRACT
Cytochrome P450 enzymes (CYPs)-mediated drug
metabolism influences drug pharmacokinetics and
results in adverse outcomes in patients through
drug–drug interactions (DDIs). Absorption, distribu-
tion, metabolism, excretion and toxicity (ADMET) is-
sues are the leading causes for the failure of a drug
in the clinical trials. As details on their metabolism
are known for just half of the approved drugs, a
tool for reliable prediction of CYPs specificity is
needed. The SuperCYPsPred web server is currently
focused on five major CYPs isoenzymes, which in-
cludes CYP1A2, CYP2C19, CYP2D6, CYP2C9 and
CYP3A4 that are responsible for more than 80%
of the metabolism of clinical drugs. The predic-
tion models for classification of the CYPs inhibi-
tion are based on well-established machine learn-
ing methods. The models were validated both on
cross-validation and external validation sets and
achieved good performance. The web server takes
a 2D chemical structure as input and reports the
CYP inhibition profile of the chemical for 10 mod-
els using different molecular fingerprints, along
with confidence scores, similar compounds, known
CYPs information of drugs––published in litera-
ture, detailed interaction profile of individual cy-
tochromes including a DDIs table and an over-
all CYPs prediction radar chart (http://insilico-cyp.
charite.de/SuperCYPsPred/).The web server does
not require log in or registration and is free to use.
INTRODUCTION
A successful drug candidate is often characterized by stick-
ing an appropriate balance of potency, efficacy, safety and
favourable pharmacokinetics (1). In other words, the sub-
tle distinction between drug efficacy and toxicity are con-
trolled by the interplay of pharmacokinetic, pharmacody-
namic and genetic factors. Drug metabolism represents an
integral contributor to the many physiological processes
that govern the pharmacokinetic fate of most therapeu-
tic agents. In rudimentary terms, drug metabolism can be
described as the biological transformation of lipophilic,
nonpolar molecules to more hydrophilic, polar molecules
knowns as metabolites, which are in turn readily eliminated
from the body (2). Based on the chemical nature of bio-
transformation, the process of drug metabolism reactions
can be divided into two broad categories: phase I (oxida-
tive reactions) and phase II (conjugative reactions) (3). The
human cytochrome P450 family (phase I enzymes) con-
tains 57 isozymes and these isozymes metabolize approxi-
mately two-thirds of known drugs in human with 80% of
this attribute to five isozymes––1A2, 3A4, 2C9, 2C19 and
2D6 (3). Most of these CYPs responsible for phase I reac-
tions are concentrated in the liver (3). Drug safety is a ma-
jor challenge in bringing new drugs to market––especially
with a majority of polytreated patients (4). As details on
their metabolism are known for just half of the approved
drugs, a tool for reliable prediction of CYPs specificity is
needed. Unexpected toxicities due to drug-drug interac-
tions (DDIs) are a major source of adverse effects con-
cerning the post-marketing safety of the drugs, which re-
sults in unexpected morbidity and mortality (3). The eval-
uation of the interactions of CYPs with small molecules
(such as drugs) constitutes a fundamental step for drug de-
sign, as well as for toxicity assessment. The DDIs is one
of the major risks associated with the pre-clinical screen-
ing of drugs, undesired DDIs can results in enhancement
of drugs toxicity or reduction of therapeutic efficacy (3).
Most DDIs are known to mediated via CYPs, such in-
teractions may indeed increase for genetic variants (with
frequent CYPs polymorphisms ‘poor metabolizers’ or in-
hibitors) or increased metabolism (with ‘rapid metaboliz-
ers’ or CYPs inducers). Food and Drug Administration
(FDA) guidance documents includes pre-screening of drugs
for CYPs inhibition and induction (5). CYPs–drug inter-
actions are responsible for several unwanted adverse ef-
fects resulting in alteration of drug pharmacokinetics, such
as changes in plasma concentration-time profiles of drugs
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when given concomitantly (5). Polymedication in elderly pa-
tients is a well-established source of variability in drug re-
sponse. Adverse drug reactions (ADRs) effects induced by
DDIs may result in early termination of drug development
or even withdrawal of drugs from the market (such as in
the case of mibefradil and cerivastatin) (3). As estimated by
a US meta-analysis––the incidence of severe side effects is
6.7% due to ADRs and results in 100 000 deaths yearly (4).
Therefore, to avoid undesirable DDIs, a screening test for
new drug candidates’ is regularly performed by pharmaceu-
tical companies. Traditionally, in vivo and in vitro tests are
performed to investigate drug safety, and adverse drug ef-
fects. Currently, experimental cellular assays on human hep-
atocytes are being used to evaluate the CYP metabolism of
the drug candidates and its possible risk (5). However, there
are few challenges associated with the in vitro testing such
as it is time-consuming, lacks the ability to provide infor-
mation on the structure-activity relationship data. In con-
trast, computational approaches are faster for evaluation of
large number of compounds and can be applied at the early
phase of drug design owing to their low cost (6). In silico ap-
proaches have the strength to predict the activities of hypo-
thetical compounds, which are yet to be synthesized. In the
past several years, a variety of computational approaches
have been used to develop classification models for the pre-
diction of chemical activities (2,7–8).
Several studies have been reported in the literature for
the screening of CYP450 inhibition based on quantita-
tive structure-activity relationship (9), molecular dynam-
ics simulation and recently machine learning (ML) meth-
ods (9,10). Several of themvNN-ADMET (11), AdmetSAR
(12), WhichCyp (13) are designed for the prediction of cy-
tochrome inhibition.
We present SuperCYPsPred web server which includes
ML models based on the RF algorithm (14), and different
types of data sampling methods (7). The models presented
here discriminate the inhibitors from the non-inhibitors
for five major CYP450 isoforms. The statistical signifi-
cance of the predictive models was assessed by the 10-fold
fragment-based CLUSTER cross-validation for the train-
ing sets, models were evaluated on different criteria like pre-
diction accuracy, sensitivity, specificity, area under the curve
(AUC) of a receiver operating characteristic (ROC) and F1
measure. The applicability domain of the models was as-
sessed using fragment-based and structural similarity-based
approaches. Apart from predicting a particular compound
as active (inhibitor) or inactive (non-inhibitor) for a defined
CYPs isoform, the web server also shows most similar com-
pounds in the training set, including if there are known cy-
tochrome interactions available for the input compound in
the literature. Additionally, each model prediction perfor-
mance was validated by the external test set. The Super-
CYPsPred web server enables user to check DDIs to un-




SuperCYPsPred data is stored in a relational MySQL
database. RDKit package (http://www.rdkit.org/) is used
for handling the chemical information in the database.
ChemDoodle Web components (https://web.chemdoodle.
com/), an open source, JavaScript library for chemistry in-
terface was used in the server. The website back-end is
built using PHP and Python; web access is enabled via the
Apache HTTP Server. Redis is employed for queuing and
assessing the API requests (8). The server has been tested
on the recent version of Mozilla Firefox, Google Chrome
and Apple Safari.
Input and output
The user interface of the SuperCYPsPred is easy-to-use and
self-informative. The web server offers the user four ways
to submit small molecules. The user can upload a standard
molecule file, name of the molecule, draw a molecule or en-
ter SMILES (Simplified Molecular-Input Line-Entry Sys-
tem) string of the compound. Optionally, the user may se-
lect different models or all models for prediction, including
different molecular fingerprints. The results are displayed in
tabular format and radar plot in the browser and includes
themolecular structure with the physicochemical properties
and the three most similar molecules from the training set
that gave the most important contribution to the decision
of the CYPs prediction models. The user can access the re-
sult in the results section, in case the prediction results can-
not be shown immediately. These prediction results are also
displayed as a radar plot comparing the average confidence
score of the active compounds in the training set of each
model, to that of the input compound (see Figure 1). Via
the DDIs checker available on the web server user can un-
derstand the likelihood of DDIs when given a combination
of medications as well get information on alternative drugs
that can be used with the same therapeutic effects.
Datasets
The training set for the models was collected from litera-
ture and two different databases. A total of 17 143 sub-
stances tested using quantitative high-throughput screen-
ing with in vitro bioluminescent assay against five major
isoforms of CYPs was obtained from the PubChem Bioas-
say database, AID: 1815 (15). Much of the information
on the cytochrome P450 enzymes were extracted from the
literature using our in-house data mining platform and
stored in the SuperCYP database (16). This database cur-
rently contains information on 1170 drugs with more than
3800 known interactions. Inorganic compounds, salts and
mixtures as well as entries classified as inconclusive were
removed from the final dataset. For each of the five cy-
tochromes, compounds were divided into training and ex-
ternal validation set, keeping the ratio of the actives (in-
hibitors) and inactives (non-inhibitors) constant (See Sup-
plementary Data S1).
Evaluation of the SuperCYPsPred models
Each model was validated using 10-fold CLUSTER cross-
validation. The data was divided using different sampling
methods and keeping the ratio of active and inactive in-
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Figure 1. Illustration of an example compound (sertraline) used as an application case. Sertraline is the input compound; the user can choose either
MACCS or Morgan fingerprints or both for the prediction. In this case both were selected. The results displayed shows the cytochrome inhibition profile
for the five major isoforms. The result page also includes information on similar compounds, with known CYPs reported in literature and overall radar
plot. The DDI matrix shows the cytochrome–drug interactions of sertraline, when given with combination with drugs (such as cisapride or ibuprofen) can
results in major interactions with side effects (please check the DDI example on the server for more details).
work (7). Additionally, an external set was used for the eval-
uation of the predictive capacity of eachmodel. Eachmodel
was evaluated by the following parameters:
• Prediction Accuracy is defined as the ability of a model to
differentiate actives and inactives cases correctly.
• Sensitivity is themodel’s ability to correctly identify the pos-
itive instances.
• Specificity is defined as the model’s ability to correctly iden-
tify the negative instances.
• The AUC of a ROC curve plots the true positive rate against
the false positive rate at different thresholds. The AUC-
ROChas been used as an effectivemeasure for binary clas-
sifiers (17).
• F1 measure is a measure of a test’s accuracy and is defined
as the weighted harmonic mean of the precision and recall
of the test.
All cross-validations and external set validation results
for the best performing CYPs isoform models are summa-
rized with respect to the different performance measures in
Table 1. Most for the models achieved a prediction accu-
racy of 90% and higher, except for 2D6 for cross-validation
and 2D6, 3A4 for external validation. The specificity and
sensitivity of all the models are balanced, and scored above
85% and above, exception 2D6, 2C9 on external sets. The
least ROC-AUC value of the models is 85% and the highest
is 99% (Table 1).
Prediction models
The SuperCYPsPred prediction models were developed by
ML approaches. These models enable a data-driven ap-
proach to cytochrome activity predictions that can iden-
tify chemical patterns that otherwise would be overlooked.
These models are based on traditional ML-like Random
Forest (RF) which can produce interpretable models with
low complexity (14). Ensemble learning algorithms such as
RF are less susceptible to class bias and overfitting. The op-
timal parameters of the RF models were determined using
the grid search method, which is implemented by the Scikit-
learn package (version 0.20) in Python (version 3.6.6), and
the 10-fold cross-validation was used for the model op-
timization. Two different chemical based fingerprints are
used: MACCS molecular fingerprints-166 bits and Mor-
gan circular fingerprints-2048 bits (http://www.rdkit.org/).
These two fingerprints have shown an optimal performance
for the prediction of chemical activity for several prediction
methods (7,18). A detailed information on the construction
of the models and evaluation can be found at the web server
FAQ section as well as in the published work (7). Data cu-
ration and standardization of the SMILES strings in the
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Table 1. Statistics for the models applied to fragment-based CLUSTER cross-validation and external validation sets
Cytochromes isoforms 1A2 2C9 2C19 2D6 3A4
Data sampling method SMOTETC SMOTETC RandOS kMediods1 AugRandUS
Chemical fingerprints Morgan Morgan MACCS MACCS Morgan
Cross-validation Prediction
Accuracy
0.95 0.97 0.97 0.84 0.92
Sensitivity 0.97 0.97 0.99 0.88 0.93
Specificity 0.97 0.96 0.94 0.86 0.92
ROC-AUC 0.99 0.98 0.97 0.92 0.96
F-measure 0.93 0.94 0.99 0.85 0.92
External validation Prediction
Accuracy
0.90 0.90 0.95 0.80 0.86
Sensitivity 0.84 0.61 0.95 0.80 0.82
Specificity 0.92 0.94 0.95 0.79 0.87
ROC-AUC 0.95 0.97 0.87 0.85 0.93
F-measure 0.76 0.58 0.98 0.60 0.74
individual models and the feature responsible for class pre-
dictions are provided in the ’Model Information’ section of
the web server.
Model CYP3A4. The most abundant hepatic CYP hu-
man isoform is CYP3A4, and the metabolism of almost
50% clinically approved drugs is mediated by this isoform
(5). The undesired CYP3A4 inhibition by co-administered
drugs can results in clinically adverse DDIs. The CYP3A4
model is based on RF algorithm and Augmented Random
Under Sampling (AugRandUS) data sampling method (7).
This model has a prediction accuracy of 92% on cross-
validation and 86% on external validation. The AUC-ROC
values of cross-validation and external validation are 0.96
and 0.93, respectively (Table 1).
Model CYP1A2. CYP1A2 is an important metabolizing
enzyme in the human liver, which accounts for 13% of the
total hepatic CYPs and is responsible for the metabolism of
4%marketed drugs (5). The CYP1A2model is based onRF
algorithm and Synthetic Minority Over-Sampling Tech-
nique using Tanimoto Coefficient (SMOTETC) data sam-
pling method (7). The CYP1A2 model has achieved predic-
tion accuracy of 95% on cross-validation and 90% on ex-
ternal validation. The AUC-ROC values of cross-validation
and external validation are 0.99 and 0.95, respectively (Ta-
ble 1).
Model CYP2C9. Approximately 20% of the total hepatic
CYPs include CYP2C9 isoform. This isoform is involved
in many clinically relevant drug interactions and is respon-
sible for the metabolism of 15% of the clinically approved
drugs (5). The CYP2C9 model is based on RF algorithm
and SMOTETC data sampling method (7). The CYP2C9
model has achieved prediction accuracy of 97% on cross-
validation and 90% on external validation. The AUC-ROC
values of cross-validation and external validation are 0.98
and 0.97, respectively (Table 1).
Model CYP2C19. CYP2C19 contributes to about 16% of
total hepatic content. This enzyme genetic polymorphism
may affect several clinically important drugs with narrow
therapeutic index (5). The CYP2C19 model is based on the
RF algorithm and Random Over Sampling (RandOS) data
sampling method (7). The CYP2C19 model has achieved
prediction accuracy of 97% on cross-validation and 95%
on external validation. The AUC-ROC values of cross-
validation and external validation are 0.97 and 0.87, respec-
tively (Table 1).
Model CYP2D6. CYP2D6 only accounts for 2–4% of the
total hepatic CYPs; however it is responsible for ∼30%
of all marketed drugs (5). The CYP2D6 model is based
on the RF algorithm and K-Medoids Under Sampling
(kMedoids1) data sampling method (7). The CYP2D6
model has achieved prediction accuracy of 84% on cross-
validation and 80% on external validation. The AUC-ROC
values of cross-validation and external validation are 0.92
and 0.85, respectively (Table 1).
Drug–Drug Interactions (DDIs)
DDIs are a major concern in the clinical field owing to
the aging population and increase of prescription of multi-
ple medications. Numerous adverse drug interactions have
been identified and reported in literature and electronic
health records (ECRs) (4). If two or multiple drugs are
prescribed at the same time, DDIs have shown to delay,
decrease or enhance the absorption of one or more of
the drugs present in the combination. This can cause se-
vere side effects either by decreasing or increasing the ac-
tion of the drugs (such as in the case of fluoxetine and
phenelzine, digoxin and quinidine, sildenafil and isosorbide
mononitrate) (20). Therefore, the initial screening of pos-
sible drug–CYP inhibitors interaction is required to high-
light the potential clinically relevant complications associ-
ated with such interactions. On the other hand, drugs can be
intentionally combined to take advantage of CYP450 inhi-
bition. Such in the case of the drug ritonavir, a protease in-
hibitor and potent CYP3A4 inhibitor. This drug is added to
lopinavir, another protease inhibitor, to boost serum levels
in patients with human immunodeficiency virus (3). An up-
dated version of the SuperCYPdatabase was used to predict
the likelihood of DDIs when given a combination of medi-
cations (16). The DDIs matrix in the SuperCYPsPred web
server is based on manually curated dataset from literature
(known interactions with reference) as well as prediction
based on computational models (unknown interactions).
Additionally, the interpretation of results from different
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understanding of the mechanisms leading to DDIs. With
the help of DDIs checker assessible via the SuperCYPsPred
web server, user can check if the metabolisms of the multi-
ple drug combinations (also known as drug cocktail) inter-
act with each other. User can provide a list of drugs name
such as enalapril (angiotensin converting enzyme (ACE)-
inhibitor) and tasosartan (angiotensin II (AT2)-receptor
blocker) and submit the names through ‘get interactions’
button. The resulting table will then contain information
on the metabolic enzymes for each drug and the mode of
activity (substrate, inhibitor or inducer). In this case both
are substrates of CYP3A4; the table additionally provides
alternatives drug with the same therapeutic effect that do
not interact with each other (e.g. enalapril and candesartan
(CYP2C9) (16).
Application case
As an application case, Sertraline is been chosen in order
to show the functionality of the web server and to dis-
cuss the results in detail. Sertraline is an antidepressant
belongs to the class of drugs known as selective reuptake
inhibitors (SSRIs). Sertraline is widely used to treat de-
pression, panic, anxiety or obsessive-compulsive symptoms.
Sertraline interactions with drugs like aspirin, cimetidine,
ibuprofen and Monoamine Oxidase (MAO) inhibitors can
change the course of action of sertraline andmay cause a se-
rious (sometimes fatal) drug interaction (20). In the Figure
1, sertraline is used as the input compound. The user has
the possibility to choose the different models or all mod-
els, including the choice of molecular fingerprints. The re-
sulting page will then show the physicochemical properties
and similar compounds from the training set, along with
the resulting table which contains the CYPs isoforms and
prediction confidence respectively. The table in this case
shows sertraline is active for five major isoforms with vari-
able (weak to strong) confidence scores. Additionally, the
radar plot enables the user to understand the prediction
strength of the input compound as compared to average
prediction strength achieved by the respective model on the
training set compounds. The DDI results shows drugs (ser-
traline, cisapride) taken in combination can result in ma-
jor drug interaction. Sertraline is an inhibitor/substrate for
five major CYPs (shown in yellow). On the other hand, cis-
apride, a gastrokinetic agent also shown to interact with five
major CYPs isoforms (shown in yellow). This drug combi-
nation is avoided by the medical practitioners as this can
increase the risk of an irregular heart rhythm and may re-
sult in potential life-threatening condition. An alternative
drug as a replacement for cisapride (shown in green) is high-
lighted. The alternative drug is suggested when the drug is
not known or predicted to bind with any CYPs isoforms.
User can click on the drug or cytochrome name to get detail
information. For each cytochrome, synonyms, Uniprot ID
as well as known drug interactions along with the type of in-
teraction and literature source are provided. For the drugs,
CID, known CYPs interaction with the type of interactions
including the Phase2 interactions profile and half-life are
shown.
CONCLUSION AND FUTURE UPDATES
The adverse effect of DDIs contributes largely to drug tox-
icity. Though it is often interpreted the toxicity of drug
metabolites can be only be determined empirically; how-
ever, learning from previously reported ADRs data can de-
mand intensive drug testing for potentially toxic drugs (21).
Here, we present SuperCYPsPred web server which imple-
ments the state-of-artMLmethods to build predictivemod-
els for five major cytochromes involved in the metabolism
of most clinically available drugs. The computational mod-
els are focussed on the first step of the safety assessment.
That is, if a particular compound is active (inhibitor) or
inactive (non-inhibitor) for a defined CYPs isoform. The
outcome of these predictions helps us to compute probabil-
ity of a compound to be highly active or slightly active for
the CYPs, rather than its exact activity value. When com-
pared with other standard published predictive models for
CYP inhibition (11,12), all the models of SuperCYPsPred
performed from the range of comparatively good to bet-
ter in some cases. However, a fair comparison using per-
formance measures like accuracy, sensitivity, specificity and
AUC-ROC has been provided as Supplementary Data S2
and S3.
One of the major challenges of computing any predic-
tion models is the availability of quality data required for
such predictions. Currently, SuperCYPsPred web server
only contains models for CYPs inhibition. In future, when
sufficient standard data are obtained, models for substrate
and inducer prediction will be made available via the web
server updates.
We hope that the understanding of the DDIs enabled via
SuperCYPsPred web server will help to approximately ad-
just or reinvent research and development strategies. This
is important in order to overcome the attrition during the
clinical trial phases of drug discovery and post-market with-
drawal of approved drugs. The application of SuperCYP-
sPred web server will include the identification of useful
CYPs inhibitors as well as assessment of new drug candi-
dates for its clinically relevant DDIs potential.
As an evolutionary step, SuperCYPsPred will focus on
method development to foster better characterization of
clinically relevant adverse effects associated with undesired
DDIs, considering genetic polymorphisms of individual
CYPs. Furthermore, to maintain the high standard of the
SuperCYPsPred web server, regular updates will be exe-
cuted, including addition of new models for the prediction
of substrates and inducers.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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